EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer from parp Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Johannes Ettl speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the EMBRACA trial.nnHe explains that the trial looked at outcomes of the PARP inhibitor talazoparib versus chemotherapy to treat patients with advanced breast cancer and a germline BRCA mutation who had received chemotherapy prior to taking part in the trial. nnDr Ettl reports that they found there was a benefit to using talazoparib in terms of reponse rate, duration of response, prog
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)